CS230492A3 - Oral pharmaceutical preparation containing cyclosporin and process forpreparing thereof - Google Patents

Oral pharmaceutical preparation containing cyclosporin and process forpreparing thereof Download PDF

Info

Publication number: CS230492A3
Authority: CS; Czechoslovakia
Prior art keywords: cyclosporin; parts; solution; volume; polyoxyethylene
Prior art date: 1990-11-27

Application number

CS922304A

Other languages

Czech (cs)

English (en)

Inventor

Erno Dr Orban

Laszlone Dr Tomori

Maria Kurthy

Tibor Dr Balogh

Laszlo Dr Jaszlits

Imre Moravcsik

Istvan Dr Kovacs

Istvanne Jusziin

Sandor Jancso

Erzsebet Dr Takacz

Tamasne Dr Kiss

Antalne Dr Kovacz

Original Assignee

Biogal Gyogyszergyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-27

Filing date

1992-07-23

Publication date

1992-12-16

1992-07-23 Application filed by Biogal Gyogyszergyar filed Critical Biogal Gyogyszergyar

1992-12-16 Publication of CS230492A3 publication Critical patent/CS230492A3/cs

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 45
108010036949 Cyclosporine Proteins 0.000 title claims abstract description 45
229960001265 ciclosporin Drugs 0.000 title claims abstract description 38
229930182912 cyclosporin Natural products 0.000 title claims abstract description 38
229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 36
238000004519 manufacturing process Methods 0.000 title abstract description 4
239000008183 oral pharmaceutical preparation Substances 0.000 title description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 51
-1 polyoxyethylene Polymers 0.000 claims abstract description 34
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
239000000203 mixture Substances 0.000 claims abstract description 24
229920000642 polymer Polymers 0.000 claims abstract description 21
229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 17
229920001451 polypropylene glycol Polymers 0.000 claims abstract description 17
229940100688 oral solution Drugs 0.000 claims abstract description 14
239000004480 active ingredient Substances 0.000 claims abstract description 11
108010019249 cyclosporin G Proteins 0.000 claims abstract description 9
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims abstract description 8
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims abstract description 8
238000000034 method Methods 0.000 claims description 20
108010036941 Cyclosporins Proteins 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 14
239000004094 surface-active agent Substances 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 4
238000001914 filtration Methods 0.000 claims description 2
238000010521 absorption reaction Methods 0.000 abstract description 8
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000243 solution Substances 0.000 description 35
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
238000003756 stirring Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000000654 additive Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
229920001983 poloxamer Polymers 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
235000015112 vegetable and seed oil Nutrition 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920002507 Poloxamer 124 Polymers 0.000 description 2
235000009470 Theobroma cacao Nutrition 0.000 description 2
244000299461 Theobroma cacao Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000035622 drinking Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000002906 microbiologic effect Effects 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229940093448 poloxamer 124 Drugs 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
239000004627 regenerated cellulose Substances 0.000 description 2
238000012430 stability testing Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000008399 tap water Substances 0.000 description 2
235000020679 tap water Nutrition 0.000 description 2
230000009967 tasteless effect Effects 0.000 description 2
239000012085 test solution Substances 0.000 description 2
CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 1
SRETXDDCKMOQNE-UHFFFAOYSA-N 2,3-bis(4-methoxyphenyl)-1h-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=CC=CC=C2N1 SRETXDDCKMOQNE-UHFFFAOYSA-N 0.000 description 1
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010016228 Fasciitis Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
240000006240 Linum usitatissimum Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000011161 development Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000004083 gastrointestinal agent Substances 0.000 description 1
229940127227 gastrointestinal drug Drugs 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
229960002867 griseofulvin Drugs 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940116406 poloxamer 184 Drugs 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229940106032 poloxamer 335 Drugs 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008646 thermal stress Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CS922304A 1990-11-27 1992-07-23 Oral pharmaceutical preparation containing cyclosporin and process forpreparing thereof CS230492A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU907653A HU208491B (en)	1990-11-27	1990-11-27	Process for producing oral pharmaceutical composition containing cyclosporin
PCT/HU1991/000050 WO1992009299A1 (en)	1990-11-27	1991-11-27	Oral pharmaceutical composition containing cyclosporin and process for preparing same

Publications (1)

Publication Number	Publication Date
CS230492A3 true CS230492A3 (en)	1992-12-16

Family

ID=10972318

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS922304A CS230492A3 (en)	1990-11-27	1992-07-23	Oral pharmaceutical preparation containing cyclosporin and process forpreparing thereof

Country Status (18)

Country	Link
US (1)	US5430017A (fi)
EP (1)	EP0512109B1 (fi)
JP (1)	JPH082795B2 (fi)
AT (1)	ATE129898T1 (fi)
AU (1)	AU651154B2 (fi)
CA (1)	CA2072983A1 (fi)
CS (1)	CS230492A3 (fi)
DE (1)	DE69114476T2 (fi)
DK (1)	DK0512109T3 (fi)
FI (1)	FI923385A0 (fi)
HU (1)	HU208491B (fi)
IL (1)	IL100162A (fi)
MX (1)	MX9102243A (fi)
NO (1)	NO922961L (fi)
NZ (1)	NZ240762A (fi)
PT (1)	PT99623A (fi)
WO (1)	WO1992009299A1 (fi)
ZA (1)	ZA919352B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ247516A (en) *	1993-04-28	1995-02-24	Bernard Charles Sherman	Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
DE4340781C3 (de) *	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
DK0789580T3 (da)	1994-11-03	2002-09-09	Novartis Ag	Nye præparatformer for cyclosporin til oral administration med simpel sammensætning og høj biotilgængelighed, og fremgangsmåder til deres fremstilling
HU215966B (hu) *	1994-11-21	1999-07-28	BIOGAL Gyógyszergyár Rt.	Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
US6022536A (en) *	1995-08-09	2000-02-08	Schering Corporation	Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
AU764599B2 (en) *	1995-08-25	2003-08-21	Sangstat Medical Corporation	Oral cyclosporin formulations
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
WO1997007787A1 (en) *	1995-08-25	1997-03-06	Sangstat Medical Corporation	Oral cyclosporin formulations
KR20050084502A (ko)	1997-01-30	2005-08-26	노파르티스 아게	오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
DE69828496T2 (de) *	1997-03-12	2006-03-23	Abbott Laboratories, Abbott Park	Hydrophile binäre systeme zur verabreichung von cyclosporin
US5891845A (en) *	1997-11-21	1999-04-06	Fuisz Technologies Ltd.	Drug delivery systems utilizing liquid crystal structures
GB9826656D0 (en)	1998-12-03	1999-01-27	Novartis Ag	Organic compounds
US7026290B1 (en)	1998-12-30	2006-04-11	Dexcel Ltd.	Dispersible concentrate for the delivery of cyclosprin
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE290460C (fi) *
DE2907460A1 (de) *	1978-03-07	1979-09-13	Sandoz Ag	Neue resorbierbare galenische kompositionen
CH641356A5 (en) *	1979-02-27	1984-02-29	Sandoz Ag	Pharmaceutical compositions containing cyclosporin
GB8903804D0 (en) *	1989-02-20	1989-04-05	Sandoz Ltd	Improvements in or relating to organic compounds
US4649047A (en) *	1985-03-19	1987-03-10	University Of Georgia Research Foundation, Inc.	Ophthalmic treatment by topical administration of cyclosporin
SE8601624D0 (sv) *	1986-04-11	1986-04-11	Haessle Ab	New pharmaceutical preparations
CA1323306C (en) *	1987-03-05	1993-10-19	Mircea C. Popescu	Pharmacological agent-lipid solution preparation
JP2577049B2 (ja) *	1987-06-04	1997-01-29	三共株式会社	シクロスポリン製剤
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
GB2230440B (en) *	1989-02-09	1993-05-19	Sandoz Ltd	Novel cyclosporin galenic forms
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine

1990
- 1990-11-27 HU HU907653A patent/HU208491B/hu unknown
1991
- 1991-11-27 ZA ZA919352A patent/ZA919352B/xx unknown
- 1991-11-27 IL IL10016291A patent/IL100162A/en not_active IP Right Cessation
- 1991-11-27 EP EP92902040A patent/EP0512109B1/en not_active Expired - Lifetime
- 1991-11-27 MX MX9102243A patent/MX9102243A/es unknown
- 1991-11-27 AU AU89440/91A patent/AU651154B2/en not_active Ceased
- 1991-11-27 DE DE69114476T patent/DE69114476T2/de not_active Expired - Fee Related
- 1991-11-27 NZ NZ240762A patent/NZ240762A/xx unknown
- 1991-11-27 DK DK92902040.2T patent/DK0512109T3/da active
- 1991-11-27 CA CA002072983A patent/CA2072983A1/en not_active Abandoned
- 1991-11-27 PT PT99623A patent/PT99623A/pt not_active Application Discontinuation
- 1991-11-27 JP JP4500525A patent/JPH082795B2/ja not_active Expired - Lifetime
- 1991-11-27 AT AT92902040T patent/ATE129898T1/de not_active IP Right Cessation
- 1991-11-27 WO PCT/HU1991/000050 patent/WO1992009299A1/en not_active Application Discontinuation
1992
- 1992-07-23 CS CS922304A patent/CS230492A3/cs unknown
- 1992-07-27 NO NO92922961A patent/NO922961L/no unknown
- 1992-07-27 FI FI923385A patent/FI923385A0/fi not_active Application Discontinuation
1993
- 1993-05-20 US US07/915,719 patent/US5430017A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH082795B2 (ja)	1996-01-17
FI923385L (fi)	1992-07-27
NO922961D0 (no)	1992-07-27
DE69114476D1 (de)	1995-12-14
HU907653D0 (en)	1991-06-28
IL100162A0 (en)	1992-08-18
HU208491B (en)	1993-11-29
MX9102243A (es)	1992-07-08
EP0512109A1 (en)	1992-11-11
EP0512109B1 (en)	1995-11-08
NO922961L (no)	1992-09-23
ZA919352B (en)	1992-09-30
US5430017A (en)	1995-07-04
CA2072983A1 (en)	1992-05-28
PT99623A (pt)	1992-12-31
DE69114476T2 (de)	1996-04-18
AU651154B2 (en)	1994-07-14
NZ240762A (en)	1993-05-26
HUT60929A (en)	1992-11-30
IL100162A (en)	1995-11-27
FI923385A0 (fi)	1992-07-27
WO1992009299A1 (en)	1992-06-11
ATE129898T1 (de)	1995-11-15
AU8944091A (en)	1992-06-25
JPH05503306A (ja)	1993-06-03
DK0512109T3 (da)	1995-12-11

Publication	Publication Date	Title
CS230492A3 (en)	1992-12-16	Oral pharmaceutical preparation containing cyclosporin and process forpreparing thereof
KR100377058B1 (ko)	2003-06-11	경구용제약제조물
JP2662183B2 (ja)	1997-10-08	サイクロスポリン軟質カプセル剤組成物
PT93079B (pt)	1996-04-30	Processo para a preparacao de composicoes farmaceuticas que contem ciclosporinas
CA2137025A1 (en)	1995-05-31	Liquid preparations containing cyclosporin and process for preparing same
RU2185187C2 (ru)	2002-07-20	Препарат, содержащий циклоспорин (варианты), и способ его получения
SI9620014A (sl)	1998-04-30	Oralne oblike ciklosporina
CZ299948B6 (cs)	2009-01-07	Farmaceutická kompozice obsahující inhibitor lipasy a monoester sacharosy s mastnou kyselinou
WO2008022557A1 (fr)	2008-02-28	Composition liquide de sirolimus
CA2133174A1 (en)	1995-03-31	Rapamycin formulations for oral administration
GB2363572A (en)	2002-01-02	Pharmaceutical composition containing cyclosporin
JP2942556B2 (ja)	1999-08-30	シクロスポリンを含有する新規組成物
WO2010141068A1 (en)	2010-12-09	Opthalmic compositions of cyclosporin
CN104473871B (zh)	2017-03-08	一种泊沙康唑脂肪乳注射液及其制备方法
KR100341203B1 (ko)	2002-06-20	유성 비타민 함유 약학 조성물 및 이의 제조방법
SK8702001A3 (en)	2002-01-07	Cyclosporin solution
RU2185188C2 (ru)	2002-07-20	Фармацевтические композиции
KR20040055669A (ko)	2004-06-26	시클로스포린계 약학적 조성물
JPH01221312A (ja)	1989-09-04	脂溶性物質含有内服液